Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Ovarian Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Non Small Cell Lung Carcinoma NSCLC 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Triple Negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Non-Small Cell Lung Cancer With HER2- Mutations 1Neoplasms, Unknown Primary 1Neoplasms 1NSCLC 1Head and Neck Neoplasms 1First-line Advanced NSCLC Patients 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Ovarian Epithelial 1Carcinoma 1

Interventions

Cisplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Non-Small Cell Lung Cancer With HER2- Mutations × CP protocol × Clear all
NCT06430437 2026-01-21

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
300 enrolled
Thoracic

Non-Small Cell Lung Cancer With HER2- Mutations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡